TrialJournal of hematology & oncology2015

High expression of myocyte enhancer factor 2C (MEF2C) is associated with adverse-risk features and poor outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group.

George S Laszlo et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.